贵州益佰制药股份有限公司 2025 年第一次临时股东大会会议资料 贵州益佰制药股份有限公司 600594 2025年第一次临时股东大会会议资料 1/87 贵州益佰制药股份有限公司 2025 年第一次临时股东大会会议资料 目录 | 贵州益佰制药股份有限公司 2025 年第一次临时股东大会会议议程 | 3 | | --- | --- | | 议案一：《关于取消监事会的议案》 | 5 | | 议案二：《关于修订<公司章程>的议案》 | 6 | | 议案三：《关于修订<股东会议事规则>的议案》 | 39 | | 议案四：《关于修订<董事会议事规则>的议案》 | 46 | | 议案五：《关于修订<独立董事工作制度>的议案》 | 50 | | 议案六：《关于修订<董事、高级管理人员薪酬管理制度>的议案》 | 54 | | 议案七：《关于修订<防范控股股东及关联方占用公司资金专项制度>的议案 | 55 | | 议案八：《关于修订<对外投资管理制度>的议案》 | 57 | | 议案九：《关于修订<对外担保管理制度>的议案》 | 59 | | 议案十：《关于修订<关联交易决策制度>的议案》 | 61 | | 议案十一：《关于修 ...

Core Points - Guizhou Yibai Pharmaceutical Co., Ltd. is holding its first extraordinary general meeting of shareholders in 2025 on September 5, 2025, with both on-site and online voting options available [1][2] - The agenda includes the proposal to abolish the supervisory board, transferring its responsibilities to the audit committee of the board of directors, and corresponding amendments to the company's articles of association [2][3] - The company aims to enhance its governance structure and operational efficiency through these changes, aligning with relevant laws and regulations [4][5] Proposal Summaries - Proposal 1: The company proposes to cancel the supervisory board, with its functions being assumed by the audit committee of the board of directors. This change is intended to streamline governance and improve operational management [2][3] - Proposal 2: Amendments to the company's articles of association are proposed to reflect the governance changes and ensure compliance with the Company Law and other relevant regulations [4][5] - Proposal 3: The meeting will also address the voting results and resolutions from the shareholders regarding the proposed changes, ensuring transparency and accountability in the decision-making process [2][3]

证券代码：600594 证券简称：益佰制药 公告编号：2025-027 贵州益佰制药股份有限公司 关于召开 2025 年半年度业绩说明会的公告 重要内容提示： 会议召开时间：2025 年 9 月 3 日 星期三 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动方式 投资者可于 2025 年 8 月 27 日（星期三）至 9 月 2 日（星期二）16:00 前 登录上证路演中心网站首页点击"预征集问答"栏目或通过贵州益佰制药股份有 限公司（以下简称"公司"）邮箱（600594@gz100.cn）进行提问。公司将在说明 会上对投资者普遍关注的问题进行回答。 公 司 已 于 2025 年 8 月 21 日 在 上 海 证 券 交 易 所 网 站 （http://www.sse.com.cn/）披露了《贵州益佰制药股份有限公司 2025 年半年 度报告》及其摘要，为便于广大投资者更全面深入地了解公司 2025 年半年度财 务状况、经营成果，公司计划于 ...

Core Viewpoint - The traditional Chinese medicine (TCM) sector is experiencing a significant surge in stock performance, driven by strong policy support and increasing market demand for TCM products [1][2]. Group 1: Market Performance - The TCM sector has shown rapid growth, with companies like Xintian Pharmaceutical leading the charge by hitting the daily limit on stock price increases, accompanied by a notable increase in trading volume [1]. - Other companies in the sector, such as Yibai Pharmaceutical, Zhendong Pharmaceutical, and others, are also witnessing substantial gains, indicating a broad-based rally within the TCM industry [1]. Group 2: Policy Support - The Chinese government is enhancing support for the TCM industry, as evidenced by the State Council's issuance of guidelines aimed at improving TCM quality and promoting high-quality development within the sector [1][2]. - The guidelines emphasize the protection and utilization of TCM resources, as well as optimizing the industrial structure and strengthening the TCM supply chain [1]. Group 3: Market Demand - There is a growing demand for TCM driven by increasing health awareness among the population and the aging demographic, which is expected to continue fueling the sector's growth [1][2]. - The expansion of the TCM market is anticipated to create new opportunities in related fields, such as TCM raw material cultivation, which will benefit farmers and agricultural service providers [1]. Group 4: Related Sectors - The TCM research and development sector is poised to benefit from government encouragement for innovation, leading to increased investment in new TCM drugs and classic formulations [2]. - The healthcare sector is closely linked to TCM, with the development of TCM products expected to drive innovation and upgrades in healthcare offerings, including TCM therapies and wellness services [2]. Group 5: Challenges and Future Potential - Despite the positive outlook, the TCM industry faces challenges such as the need for unified quality standards and sustainable resource utilization [2]. - However, the combination of policy support, growing market demand, and the industry's own development trends suggests that the TCM sector and its related fields have significant growth potential in the future [2].

据证券之星公开数据整理，近期益佰制药（600594）发布2025年中报。根据财报显示，益佰制药亏损收 窄。截至本报告期末，公司营业总收入9.93亿元，同比下降14.99%，归母净利润-1990.21万元，同比上 升81.31%。按单季度数据看，第二季度营业总收入4.92亿元，同比下降17.45%，第二季度归母净利 润-1051.63万元，同比上升72.35%。 本次财报公布的各项数据指标表现一般。其中，毛利率60.65%，同比减2.87%，净利率-2.25%，同比增 76.3%，销售费用、管理费用、财务费用总计5.63亿元，三费占营收比56.68%，同比减12.65%，每股净 资产3.12元，同比减9.39%，每股经营性现金流0.22元，同比减16.02%，每股收益-0.03元，同比增 81.34% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 11.68 Z | 22666 | -14.99% | | 归母浄利润（元） | -1.06亿 | -1990.21万 | 81.31% | | 扣非净利润(元) | ...

截至2025年8月21日15时，益佰制药股价报4.48元，较前一交易日下跌1.54%，成交额2.51亿元。 益佰制药主营业务涵盖医药工业和医疗服务板块，主要产品包括中药制剂、化学药及医疗服务等。公司 近期因产品停产及商业贿赂风波受到市场关注。 消息面上，益佰制药披露2025年半年报，上半年营收9.93亿元，同比下降14.99%，归母净利润亏损 1990.21万元，但较去年同期亏损幅度收窄。公司拟以8000万元收购控股子公司剩余股权，以整合资 产。此外，公司小儿止咳糖浆因生产缺陷被暂停销售，但该产品占营收比例较小，预计对业绩影响有 限。 资金流向方面，益佰制药8月21日主力资金净流出2371.04万元，近五日主力资金净流入4590.07万元。 风险提示：股市有风险，投资需谨慎。 来源：金融界 ...

Group 1 - Xiamen Tungsten's revenue for the first half of 2025 reached 19.178 billion yuan, an increase of 11.75% year-on-year [1] - Xiamen Tungsten's net profit attributable to shareholders decreased by 4.37% year-on-year to 972 million yuan [1] - Xiamen Tungsten plans to distribute a cash dividend of 1.84 yuan per 10 shares [1] Group 2 - Sinopec's revenue for the first half of 2025 was 1.41 trillion yuan, a decrease of 10.6% year-on-year [1][2] - Sinopec's net profit attributable to shareholders fell by 39.8% year-on-year to 21.483 billion yuan [1][2] - Sinopec's basic earnings per share were 0.177 yuan [1] Group 3 - Xinhua Department Store's revenue for the first half of 2025 was 3.254 billion yuan, a decrease of 0.99% year-on-year [3][4] - Xinhua Department Store's net profit attributable to shareholders decreased by 2.52% year-on-year to 86.08 million yuan [3][4] - Xinhua Department Store plans to distribute a cash dividend of 1 yuan per 10 shares [3] Group 4 - Huaqin Technology's revenue for the first half of 2025 reached 516 million yuan, an increase of 6.44% year-on-year [5][6] - Huaqin Technology's net profit attributable to shareholders decreased by 32.45% year-on-year to 146 million yuan [5][6] - Huaqin Technology plans to distribute a cash dividend of 1.3 yuan per 10 shares [5] Group 5 - Tianhao Energy's revenue for the first half of 2025 was 1.372 billion yuan, a decrease of 32.15% year-on-year [7] - Tianhao Energy's net profit attributable to shareholders decreased by 32.08% year-on-year to 69.01 million yuan [7] - Tianhao Energy's basic earnings per share were 0.0798 yuan [7] Group 6 - Wanliyang's revenue for the first half of 2025 reached 2.812 billion yuan, an increase of 2.69% year-on-year [8][9] - Wanliyang's net profit attributable to shareholders increased by 50.24% year-on-year to 277 million yuan [8][9] - Wanliyang's basic earnings per share were 0.21 yuan [8] Group 7 - Kede CNC's revenue for the first half of 2025 was 295 million yuan, an increase of 15.24% year-on-year [10] - Kede CNC's net profit attributable to shareholders increased by 1.27% year-on-year to 49.06 million yuan [10] - Kede CNC's basic earnings per share were 0.4582 yuan [10] Group 8 - Saifutian's revenue for the first half of 2025 reached 1.06 billion yuan, an increase of 62.41% year-on-year [11] - Saifutian achieved a net profit of 3.08 million yuan, recovering from a loss of 12.49 million yuan in the previous year [11] - Saifutian's basic earnings per share were 0.01 yuan [11] Group 9 - Funeng's revenue for the first half of 2025 was 6.369 billion yuan, a decrease of 4.44% year-on-year [13][14] - Funeng's net profit attributable to shareholders increased by 12.48% year-on-year to 1.337 billion yuan [13][14] - Funeng plans to distribute a cash dividend of 0.73 yuan per 10 shares [13] Group 10 - Ningbo Shipping reported a net loss of 39.23 million yuan for the first half of 2025 [15][16] - Ningbo Shipping's revenue for the first half of 2025 was 1.157 billion yuan, an increase of 11.33% year-on-year [15][16] - Ningbo Shipping's basic earnings per share were a loss of 0.0325 yuan [15] Group 11 - Samsung Medical's revenue for the first half of 2025 reached 7.972 billion yuan, an increase of 13.93% year-on-year [17][18] - Samsung Medical's net profit attributable to shareholders increased by 6.93% year-on-year to 1.23 billion yuan [17][18] - Samsung Medical plans to distribute a cash dividend of 4.85 yuan per 10 shares [17] Group 12 - Huiding Technology's revenue for the first half of 2025 was 2.251 billion yuan, a decrease of 0.20% year-on-year [20] - Huiding Technology's net profit attributable to shareholders increased by 35.74% year-on-year to 431 million yuan [20] - Huiding Technology plans to distribute a cash dividend of 0.15 yuan per share [20] Group 13 - Baihua Pharmaceutical's revenue for the first half of 2025 reached 202 million yuan, an increase of 2.95% year-on-year [21] - Baihua Pharmaceutical's net profit attributable to shareholders increased by 12.45% year-on-year to 25.48 million yuan [21] - Baihua Pharmaceutical's basic earnings per share were 0.0663 yuan [21] Group 14 - Stanley's revenue for the first half of 2025 was 6.391 billion yuan, an increase of 12.66% year-on-year [22][23] - Stanley's net profit attributable to shareholders increased by 18.9% year-on-year to 607 million yuan [22][23] - Stanley plans to distribute a cash dividend of 0.45 yuan per 10 shares [22] Group 15 - Duoli Technology's revenue for the first half of 2025 reached 1.734 billion yuan, an increase of 13.15% year-on-year [24] - Duoli Technology's net profit attributable to shareholders decreased by 28.13% year-on-year to 157 million yuan [24] - Duoli Technology's basic earnings per share were 0.51 yuan [24] Group 16 - Datang Telecom reported a net loss of 81.17 million yuan for the first half of 2025 [25][26] - Datang Telecom's revenue for the first half of 2025 was 275 million yuan, a decrease of 3.32% year-on-year [25][26] - Datang Telecom's basic earnings per share were a loss of 0.0623 yuan [25] Group 17 - Niuwei Co.'s revenue for the first half of 2025 reached 3.404 billion yuan, an increase of 19.96% year-on-year [27][28] - Niuwei Co.'s net profit attributable to shareholders increased by 30.44% year-on-year to 637 million yuan [27][28] - Niuwei Co. plans to distribute a cash dividend of 5.8 yuan per 10 shares [27] Group 18 - ST Zhiyun reported a net loss of 106 million yuan for the first half of 2025 [29][30] - ST Zhiyun's revenue for the first half of 2025 was 89.13 million yuan, a decrease of 63.59% year-on-year [29][30] - ST Zhiyun's basic earnings per share were a loss of 0.37 yuan [29] Group 19 - Huace Testing's revenue for the first half of 2025 reached 2.96 billion yuan, an increase of 6.05% year-on-year [31] - Huace Testing's net profit attributable to shareholders increased by 7.03% year-on-year to 467 million yuan [31] - Huace Testing plans to distribute a cash dividend of 0.5 yuan per 10 shares [31] Group 20 - Taixiang's revenue for the first half of 2025 was 219 million yuan, an increase of 6.57% year-on-year [32] - Taixiang's net profit attributable to shareholders increased by 16.12% year-on-year to 25.30 million yuan [32] - Taixiang's basic earnings per share were 0.2533 yuan [32] Group 21 - Huayi Technology applied for a credit line of up to 165 million yuan from HSBC [33][34] - Huayi Technology will use real estate as collateral for the credit line [33][34] Group 22 - Hengong Precision plans to use up to 70 million yuan of idle raised funds for cash management [35][36] - Hengong Precision will invest in high-security, high-liquidity products with a term not exceeding 12 months [35][36] Group 23 - Tianhe's financial assistance to its associate company has not been repaid [37] - Tianhe provided 243,200 yuan in financial assistance to its associate company [37] Group 24 - Spring and Autumn Electronics' revenue for the first half of 2025 reached 1.926 billion yuan, an increase of 2.62% year-on-year [38] - Spring and Autumn Electronics' net profit attributable to shareholders increased by 248.44% year-on-year to 93.31 million yuan [38] - Spring and Autumn Electronics' basic earnings per share were 0.21 yuan [38] Group 25 - Kingsoft Office's revenue for the first half of 2025 was 2.657 billion yuan, an increase of 10.12% year-on-year [39][40] - Kingsoft Office's net profit attributable to shareholders increased by 3.57% year-on-year to 747 million yuan [39][40] Group 26 - Yanjinpuzi's revenue for the first half of 2025 reached 2.941 billion yuan, an increase of 19.58% year-on-year [41] - Yanjinpuzi's net profit attributable to shareholders increased by 16.70% year-on-year to 373 million yuan [41] Group 27 - Muyuan's revenue for the first half of 2025 was 76.463 billion yuan, an increase of 34.46% year-on-year [43][44] - Muyuan's net profit attributable to shareholders increased by 1169.77% year-on-year to 10.53 billion yuan [43][44] - Muyuan plans to distribute a cash dividend of 9.32 yuan per 10 shares [43][44] Group 28 - Tianwei Food is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [45][46] Group 29 - Alloy Investment's shareholder plans to reduce their stake by no more than 3% [47] - Alloy Investment's shareholder plans to sell up to 11.5531 million shares [47] Group 30 - Rongzhi Rixin's controlling shareholder plans to reduce their stake by no more than 3% [48] - Rongzhi Rixin's controlling shareholder plans to sell up to 1.2318 million shares [48] Group 31 - Yijiahe's shareholders plan to reduce their stake by no more than 2% [49] - Yijiahe's shareholders plan to sell up to 409.72 million shares [49] Group 32 - Dongfeng Group adjusted the upper limit of its share repurchase price to 6.28 yuan per share [50] Group 33 - Jingu's revenue for the first half of 2025 reached 2.123 billion yuan, an increase of 10.04% year-on-year [51] - Jingu's net profit attributable to shareholders increased by 45.36% year-on-year to 30.27 million yuan [51] Group 34 - Yibai Pharmaceutical reported a net loss of 19.9 million yuan for the first half of 2025 [52] - Yibai Pharmaceutical's revenue for the first half of 2025 was 999 million yuan, a decrease of 14.99% year-on-year [52] Group 35 - Yonghui Supermarket reported a net loss of 241 million yuan for the first half of 2025 [53] - Yonghui Supermarket's revenue for the first half of 2025 was 29.948 billion yuan, a decrease of 20.73% year-on-year [53] Group 36 - Suotong Development's net profit increased by 1568.52% year-on-year to 523 million yuan [54] - Suotong Development's revenue for the first half of 2025 was 8.306 billion yuan, an increase of 28.28% year-on-year [54]

Core Viewpoint - Guizhou Yibai Pharmaceutical Co., Ltd. reported a decline in revenue and net profit for the first half of 2025, indicating challenges in the pharmaceutical industry amid economic adjustments and increased competition [1][15][14]. Company Overview - Guizhou Yibai Pharmaceutical is a comprehensive pharmaceutical enterprise focusing on the entire industry chain from traditional Chinese medicine cultivation to production and sales, including chemical drugs, traditional Chinese medicine, and biological drugs [3][6]. - The company operates in various therapeutic areas, including oncology, cardiovascular, gynecology, pediatrics, orthopedics, and respiratory diseases, with a product portfolio of 152 varieties [15][16]. Financial Performance - The company reported operating revenue of approximately 993.12 million yuan, a decrease of 14.99% compared to the same period last year [2][15]. - The total profit for the period was a loss of approximately 23.85 million yuan, with a net profit attributable to shareholders of approximately -19.90 million yuan [2][15]. - The net cash flow from operating activities was approximately 170.55 million yuan, down 16.02% from the previous year [2]. Business Segments - The pharmaceutical industrial segment generated approximately 778.46 million yuan in revenue, down 15.83%, while the medical services segment generated approximately 203.81 million yuan, down 11.69% [15][16]. - The medical services segment includes the operation and management of hospitals and specialized cancer treatment centers, with a focus on providing high-quality medical services [16]. Industry Context - The pharmaceutical industry in China is experiencing a period of adjustment due to economic transformation, with overall revenue and profit declines reported across the sector [11][14]. - The industry is driven by factors such as an aging population, increasing healthcare demands, and government policies aimed at reforming the healthcare system [8][12]. - The market is expected to continue growing, supported by policy initiatives and technological advancements, despite challenges such as rising medical costs and pressure on insurance funds [9][10][12]. Strategic Initiatives - The company is committed to innovation and enhancing its core business capabilities, focusing on research and development, production technology, and sales management [6][14]. - Efforts are being made to integrate AI technology into operations to improve efficiency and decision-making processes [19][20]. - The company aims to expand its product line and market presence through strategic partnerships and collaborations in research and development [17][18].

贵州益佰制药股份有限公司2025 年半年度报告摘要 公司代码：600594 公司简称：益佰制药 贵州益佰制药股份有限公司 贵州益佰制药股份有限公司2025 年半年度报告摘要 第一节 重要提示 展规划，投资者应当到 http://www.sse.com.cn 网站仔细阅读半年度报告全文。 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 无 贵州益佰制药股份有限公司2025 年半年度报告摘要 第二节 公司基本情况 公司股票简况 股票种类 股票上市交易所 股票简称 股票代码 变更前 股票简称 A股 上海证券交易所 益佰制药 600594 无 联系人和联系方式 董事会秘书 证券事务代表 姓名 蒋先洪 周光欣 电话 0851-84705177 0851-84705177 办公地址 贵州省贵阳市云岩区白云大道220-1号 贵州省贵阳市云岩区白云大道 220-1号 电子信箱 600594@gz100.cn 600594@gz100.cn 单位：元 币种：人民币 本报告期末比上年 本报告期末 上年度末 度末增减(%) 总资产 4,052,321,538.48 4,099,701,241.48 -1 ...

证券代码：600594 证券简称：益佰制药 公告编号:2025-022 贵州益佰制药股份有限公司 第八届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 次会议通知于 2025 年 8 月 8 日以电子邮件等方式送达全体董事、监事及高管， 会议增加临时议案《关于受让控股子公司少数股权的议案》的通知于 2025 年 8 月 19 日以电子邮件等方式送达全体董事、监事及高管，全体董事一致同意增加 临时议案《关于受让控股子公司少数股权的议案》，并同意本次增加临时议案通 知的发出豁免时限的要求，本次会议召集人董事长窦啟玲女士在会议上对此作 出了说明。本次会议于 2025 年 8 月 19 日在公司行政楼会议室以现场加通讯会 议方式召开。 玲女士召集和主持。 本议案在提交公司董事会审议前已经公司第八届董事会审计委员会 2025 年第四次会议审议通过。 详情请参见公司于 2025 年 8 月 21 日披露在《中国证券报》 《证券时报》 《上 二、董事会会议审议情况 本次会议以记名投票表决方 ...